Company News
Company News
The Polaris Pharmaceutical’s new drug for mesothelioma has increased the three-year survival rate by fourfold, as published in the internationally renowned medical journal JAMA Oncology.
The breakthrough clinical trial of a rare and aggressive cancer treatment reveals: Polaris metabolic therapy drug, ADI-PEG 20, presents an innovative treatment approach that significantly enhances the survival rates of patients with malignant pleural mesothelioma (MPM), particularly demonstrating a fourfold increase in three-year survival rates compared to the placebo group.
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual- Engine Growth
TAIPEI, Taiwan and SAN DIEGO, Calif., Dec 21- Polaris Group (TWSE: 6550) announced that its board approved to increase the acquisition of Genovior Biotech’s shares to
100%. Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group. This significant decision not only allows
Polaris Group to expand the product pipeline beyond its novel cancer metabolism therapy but also marks its entry into the highly promising realm of peptide drugs, such as the widely recognized Semaglutide-related products. These two highly
prospective product lines will serve as the dual engines propelling Polaris Group’s future growth.
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
TAIPEI, Taiwan and SAN DIEGO, Calif., Nov 30 – Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with traditional chemotherapy as systemic treatment in the second or third line for LMS.
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
TAIPEI, Taiwan and SAN DIEGO, Calif., November 29— Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis (NASH).